1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,180 | 3,400 | 15:22 | |
| 3,200 | 3,360 | 15:19 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.04. | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT UPDATE ON THE LICENSE AGREEMENT WITH ASTRAZENECA ON CMG901 (AZD0901) | 1 | HKEx | ||
| 28.03. | Keymed Biosciences gibt Jahresergebnis 2023 und aktuelle Geschäftszahlen bekannt | 22 | PR Newswire | Einreichung eines Zulassungsantrags für Stapokibart (CM310) für die Behandlung von mittelschwerer bis schwerer Alzheimer-Krankheit bei Erwachsenen. Die NDA wurde von der chinesischen NMPA akzeptiert... ► Artikel lesen | |
| 26.03. | Keymed Biosciences Announces 2023 Annual Results and Business Updates | 195 | PR Newswire | Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by the China's NMPA and granted priority review.Advanced... ► Artikel lesen | |
| 26.03. | KEYMED BIO-B (02162): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION ... | 1 | HKEx | ||
| 14.03. | KEYMED BIO-B (02162): DATE OF BOARD MEETING | 1 | HKEx | ||
| 22.01. | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT SHARE PURCHASE PURSUANT TO THE 2022 RESTRICTED SHARE UNIT SCHEME | 1 | HKEx | ||
| 27.12.23 | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL TRIAL OF CM310 FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPS ACHIEVED ... | 1 | HKEx | ||
| 07.12.23 | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF STAPOKIBART FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN ADULTS ACCEPTED ... | 1 | HKEx | ||
| 08.11.23 | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT THE LATEST RESULTS FROM A PHASE I CLINICAL STUDY OF CMG901 AT THE ASCO PLENARY SERIES BY WAY OF ORAL PRESENTATION | 1 | HKEx | ||
| 15.05.23 | Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis | 362 | PR Newswire | SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences ("Keymed", HKEX: 02162), today announced a collaboration to jointly discover and develop first-in-class... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIO-PATH | 4,200 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Expands Global Patent Portfolio | HOUSTON, April 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop... ► Artikel lesen | |
| QIAGEN | 37,225 | +0,53 % | Qiagen: Aufschwung in der zweiten Jahreshälfte | Analysten der Deutschen Bank erwarten beim Jahresauftakt von Qiagen keine Überraschungen. Das Unternehmen prognostiziert einen Umsatz von rund 455 Millionen Dollar, das wäre ein Minus von rund 6 Prozent.... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 35,120 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting | New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session Nello Mainolfi, Founder, President... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,310 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 9,450 | 0,00 % | Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts | ||
| CABALETTA BIO | 13,970 | 0,00 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| JANUX THERAPEUTICS | 48,850 | 0,00 % | Janux a new buy at Jones on lead assets for solid tumors | ||
| DAY ONE BIOPHARMACEUTICALS | 15,750 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress | PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,400 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
| ARCELLX | 54,52 | 0,00 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
| EVOTEC | 13,130 | -2,38 % | Deutsche Telekom, Evotec, Morphosys, Mutares, Nel ASA - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| NUVALENT | 63,00 | 0,00 % | Jefferies starts Nuvalent at buy, cites lung cancer drug candidates | ||
| VERA THERAPEUTICS | 39,510 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 23,030 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, March 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,650 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen |
Das Unternehmen KEYMED BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,12 % bei einem Aktienkurs von 3,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
